EG 427 to hold poster presentation on lead asset EG110A at ESGCT

October 10, 2023

EG 427 announces today that it will hold a poster presentation outlining preclinical data on its lead asset EG110A at the European Society of Gene and Cell Therapy (ESGCT) 30th Annual Congress, taking place October 24-27 in Brussels, Belgium.

Julien Ratelade, Preclinical Project Manager, will present a poster on Wednesday, October 25 from 5:00-6:15pm CET and Thursday, October 26 from 8:30pm to 9:30pm CET.

Please read Press release in English and in French


Recent posts

EG 427 Announces Attendance at Conferences in H1 2024
EG 427 Announces Attendance at Conferences in H1 2024

read more >

EG 427 Announces New Preclinical Results from Multiple Studies of EG110A  in NDO and OAB
EG 427 Announces New Preclinical Results from Multiple Studies of EG110A in NDO and OAB

read more >

EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters
EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters

read more >

EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder
EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder

read more >

EG 427 announces attendance to multiple upcoming conferences in fall 2023
EG 427 announces attendance to multiple upcoming conferences in fall 2023

read more >

×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.